Unlocking potential: Virus-like particles as a promising strategy for effective HCV vaccine development.

Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. The development of prophylactic vaccine is essential for HCV global eradication. Despite over three decades of research, no effective vaccine for HCV has been developed, primarily due to the virus's genetic diversity, immune evasion mechanisms, and incomplete understanding of protective immunity.

Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals.

Background: Although direct-acting antivirals (DAAs) have revolutionized the management of chronic HCV, the debatable association with hepatocellular carcinoma (HCC) occurrence/recurrence has raised major concerns about their long-term use, especially in cirrhotic cases. The role of epithelial tight junction proteins (TJPs) in hepatocarcinogenesis has been highlighted; however, the association of their expression in peripheral blood mononuclear cells (PBMCs) with HCC has rarely been reported. This study aimed to explore the role of peripheral claudin (Cldn)1 in liver pathogenesis and its crosstalk with soluble immune mediators in HCC prognosis.

Serum thymosin beta 10 level as a potential prognosis prediction of hepatocellular carcinoma and hepatic diseases.

Thymosin Beta 10 (TMSB10) is a thymosin family member that has been identified as being overexpressed in a wide variety of human cancers. This study aimed to determine the expression level of TMSB10 in sera of patients with hepatocellular carcinoma (HCC) and liver cirrhosis. And to reveal the association between TMSB10 and different stages in patients with HCC.